AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03201081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme
Description: The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
Study NCT02836639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 0.8 mg/kg four times per day from day -7 to day -5
Study NCT02836639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 400 mg/m2 from day -5 to day -4
Study NCT02836639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 200 mg/m2 starting dose on day -3 and -2
Study NCT01705847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9820
Description: GS-9820 tablets containing 200 mg of GS-9820 administered orally
Study NCT01139008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole 1% gel
Description: Apply topically on one side of the face once daily for three weeks
Study NCT01139008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: Apply topically on the opposite side of the face twice daily for three weeks
Study NCT02102711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A oral drops
Study NCT03924557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genotype-guided Supportive Care
Description: In this arm, supportive care will be administered based on the results of the genotype test.
Study NCT03667898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block using NTT
Description: An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
Study NCT03667898 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar plexus block without NTT
Description: An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
Study NCT01601600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338
Study NCT01601600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BYM338 Placebo
Study NCT01473368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 500 mg, 2 times daily for 14 days
Study NCT01670994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
Study NCT01473368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: 875/125 mg 2 times daily at least 1 hour before meals for 7 days
Study NCT03645343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator
Description: This appliance is constructed in one piece to guide the position of the mandible on closure
Study NCT03645343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Block
Description: This appliance is constructed in two pieces to guide the position of the mandible on closure
Study NCT03348189 — intervention group
Intervention type: OTHER
Intervention: Pulse Oximeter
Description: Pulse Oximeter
Study NCT03496714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation on trauma reactions
Description: The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
Study NCT03496714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation on trauma reactions
Description: The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
Study NCT03496714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation on safety behaviors
Description: The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
Study NCT01262183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRT + Panitumumab
Description: Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
Study NCT01262183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy without panitumumab
Description: Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
Study NCT02730156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Altitude exposure
Study NCT02775929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FTC-TDF PrEP
Description: FTC-TDF PrEP for HIV-1 uninfected partners
Study NCT02775929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ART
Description: ART for HIV-1 infected partners
Study NCT02903459 — intervention group
Intervention type: OTHER
Intervention: Transversal Study so there is no intervention
Study NCT02465554 — intervention group
Intervention type: PROCEDURE
Intervention: Myocardial contrast echocardiography
Description: Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
Study NCT01062373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of lactating mothers who has delivered prematurely with DHA
Description: Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
Study NCT01062373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of lactating mothers who has delivered prematurely with DHA
Description: Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
Study NCT02889744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Sun
Description: Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
Study NCT04249232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide 80 micrograms per Pen dose
Description: prefilled injector pen to deliver 80 micrograms daily subcutaneously
Study NCT04249232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo prefilled injector pen
Description: prefilled injector pen to deliver inactive solution daily subcutaneously
Study NCT03074019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylooligosaccacharide
Description: XOS95 powder
Study NCT03074019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin powder
Study NCT00927004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Description: 60 mg, daily dose, oral delivery, 14 days duration
Study NCT00927004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Daily dose (1 pill), oral delivery, 14 days
Study NCT03029988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept (Technetium Tc 99m tilmanocept Injection)
Description: Drug: Technetium Tc 99m tilmanocept
Study NCT03029988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT Imaging
Description: 4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
Study NCT03736915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection using 1 cc of NaCl 0.9%
Description: The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
Study NCT03736915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Question
Description: Patient is asked at the end of each injection which injection they prefer
Study NCT03736915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient is asked to answer questionairres at the end of each injection
Study NCT03504176 — intervention group
Intervention type: OTHER
Intervention: Ventilation bundle
Description: ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
Study NCT01112449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active medication
Study NCT01112449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: 200 µg/day of selenomethionine (SM)
Study NCT01112449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose selenized-yeast
Description: 200 µg/day of SY
Study NCT01112449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose selenized-yeast
Description: 285 µg/day of SY
Study NCT05003297 — intervention group
Intervention type: OTHER
Intervention: hemogram inflammatory parameters
Description: Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
Study NCT01502215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
Study NCT01502215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
Study NCT02894502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
Study NCT00472680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction, high protein
Description: Weight loss with higher protein (35%) intake
Study NCT00472680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction; normal protein
Description: Weight loss with normal level of protein (18%) intake
Study NCT00472680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
Study NCT00472680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
Study NCT04316403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: This application was made before the onset of canine retraction in one side of the mouth
Study NCT02494063 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy
Description: Bilateral sentinel lymph node biopsy, pathologic ultrastaging
Study NCT03110588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACE with Cabazitaxel (15 mg/m2)
Description: Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
Study NCT03110588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACE with Cabazitaxel (20 mg/m2)
Description: Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
Study NCT02840851 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
Study NCT02840851 — intervention group
Intervention type: DEVICE
Intervention: TCD
Description: Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
Study NCT03484715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
Study NCT03168815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula or Low Flow Nasal Cannula
Description: HFNC vs LFNC
Study NCT03168815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula or Low Flow Nasal Cannula
Description: HFNC vs LFNC
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: subcutaneous, single dose 0.3 mg/kg
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous normal saline single dose
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous, single dose 1.0 mg/kg
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous single dose 3 mg/kg
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous single dose 6 mg/kg
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Intravenous infusion single dose 1 mg/kg
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion normal saline single dose
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06293620
Description: Subcutaneous injection multiple dose TBD mg (Days TBD)
Study NCT02211261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection normal saline multiple dose (Days TBD)
Study NCT05179616 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter edge-to-edge tricuspid valve repair
Description: Percutaneous edge to edge repair of tricuspid valve using the TriClip system
Study NCT02494063 — intervention group
Intervention type: PROCEDURE
Intervention: At least unilateral systematic pelvic lymph node dissection
Study NCT02553252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga Trauma Relief Program (SKY)
Description: Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
Study NCT04352972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-monitored home exercise program
Description: Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
Study NCT04352972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based rehabilitation program
Description: Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
Study NCT02265588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
Study NCT04958395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FFR and d-FFR
Description: Measure FFR and d-FFR
Study NCT05197660 — intervention group
Intervention type: PROCEDURE
Intervention: surgical procedures
Description: number of hospital stays
Study NCT01873612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response
Study NCT01873612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnic ventilatory response
Study NCT04294056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
Study NCT04294056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
Study NCT02870933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transepicardial with Transseptal CD 133+ Implantation
Description: Transepicardial with Transseptal CD 133+ Implantation
Study NCT03505840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with Doppler and 3D technology
Description: ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
Study NCT03196492 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02809040 — intervention group
Intervention type: OTHER
Intervention: Electrocardiogram/Echocardiography
Description: Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart.
Study NCT02809040 — intervention group
Intervention type: OTHER
Intervention: Portable digital auscultation
Description: Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation
Study NCT00601042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish snus (smokeless tobacco)
Description: Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
Study NCT00601042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Onico
Description: Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
Study NCT00511394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Human Albumin
Description: Infusion of 100 mL of 20% Albumin over 3 hours
Study NCT00511394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Infusion of 100 mL of Normal Saline